Wave Life Sciences, Inc.

Rule 10b5-1 Trading Plans

During the three months ended March 31, 2025, certain of our officers (as defined in Rule 16a-1(f) of the Exchange Act) entered into contracts, instructions or written plans (each, a “Rule 10b5-1 Trading Plan” and collectively, the “Rule 10b5-1 Trading Plans”) for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. We describe the material terms of these Rule 10b5-1 Trading Plans below.

On March 13, 2025, Kyle Moran, CFA, our Chief Financial Officer, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 296,000 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Mr. Moran’s Rule 10b5-1 Trading Plan is active until March 16, 2026, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.

On March 13, 2025, Aik Na Tan, a member of our board of directors, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 156,345 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Ms. Tan’s Rule 10b5-1 Trading Plan is active until September 15, 2025, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.

On March 13, 2025, Gregory Verdine, Ph.D., a member of our board of directors, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 60,000 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Dr. Verdine’s Rule 10b5-1 Trading Plan is active until December 31, 2025, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.

On March 13, 2025, Heidi Wagner, a member of our board of directors, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 97,500 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Ms. Wagner’s Rule 10b5-1 Trading Plan is active until March 1, 2026, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.

Except as disclosed above, none of our directors or executive officers adopted, modified orterminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as such term is defined in Item 408(a) of Regulation S-K, during the fiscal quarter ended March 31, 2025.